Pharmacor Analyst Calls
Pharmacor analyst calls are available exclusively to clients who subscribe to the Pharmacor advisory service being featured in the online presentation. Recordings of the presentations are also available for playback following each session. Topics covered in Pharmacor analyst calls include detailed and timely analysis on:
- How a newly launched drug will compete in the market and how it will impact the market share of other currently marketed therapies
- What the impact of corporate announcements and presentations at biopharmaceutical conferences will have on the marketplace
- How a drug’s regulatory rejection will impact the market, including insight on what other existing therapies will inherit the failed agent’s market share
- How positive clinical trial data will impact thought leaders’ perceptions of a drug candidate and how that agent would be prescribed if approved
- How a market currently dominated by a certain drug class will evolve as emerging therapies from other drug classes steal share from dominant therapies over time
- Which agents in a crowded therapeutic pipeline are best positioned to have the greatest impact on treatment and, as a result, will be the most successful
Below is a listing of our upcoming and on demand Pharmacor analyst calls:
-
December 20, 2011
Based on our Pharmacor
Breast Cancer advisory service, Decision Resources is offering this exclusive analyst call entitled
Breast Cancer: The Emergence of Pertuzumab, Highlights from SABCS and Other Recent Market Events.
This analyst call was recorded live on December 20, 2011.
Contact us to learn how you can access the recorded playback.
Click here to view the invite.
-
December 1, 2011
Based on our Pharmacor
Hepatitis C Virus advisory service, Decision Resources is offering this exclusive analyst call entitled
Interferon-Free Therapies for Hepatitis C Virus Take Center Stage - Highlights from AASLD’s 2011 Liver Meeting.
This analyst was recorded live on December 1, 2011.
Contact us to learn how you can access the recorded playback.
Click here to view the invite.
-
November 29, 2011
Based on our Pharmacor advisory service entitled
Acute Coronary Syndrome, Decision Resources is offering this exclusive analyst call entitled
Mixed Fortunes for Xarelto and Vorapaxar in Acute Coronary Syndrome – What Does the Future Hold for These Novel Oral Antithrombotics?
This analyst call was recorded live on November 29, 2011.
Contact us to learn how you can access the recorded playback.
Click here to view the invite.
-
October 26, 2011
Based on our Pharmacor
Prostate Cancer advisory service, Decision Resources is offering an exclusive analyst call entitled
Prostate Cancer: Navigating Through the Maze of Market-Relevant Patient Populations.
This analyst call was recorded live on October 26, 2011.
Contact us to learn how you can purchase this service and access the recorded playback.
Click here to view the invite.
-
October 25, 2011
Based on our Pharmacor
Ovarian Cancer advisory service, Decision Resources is offering this exclusive analyst call entitled
Ovarian Cancer: Avastin Will Revolutionize Therapeutic Options and Will Pave the Way for Targeted Therapy Approvals.
This analyst call was recorded live on October 25, 2011.
Contact us to learn how you can access the recorded playback.
Click here to view the invite.
-
October 18, 2011
Based on our Pharmacor
Breast Cancer advisory service, Decision Resources is offering this exclusive analyst call entitled Targeted Therapies in Breast Cancer – Everolimus Takes Center Stage at ECCO-ESMO.
This analyst call was recorded live on October 18, 2011.
Contact us to learn how you can purchase this service and access the recorded event.
Click here to view the invite.
-
August 16, 2011
Based on our Pharmacor
Atrial Fibrillation advisory service, Decision Resources is offering an exclusive analyst call entitled
Atrial Fibrillation: Will Emerging Agents With Novel Mechanisms of Action Overcome the Limitations of Current Treatments?
This analyst call was held on August 16, 2011.
Contact us to learn how you can purchase this service and access the recorded event.
Click here to view the invite.
-
July 6, 2011
Based on our Pharmacor
Multiple Sclerosis advisory service, Decision Resources is offering an exclusive analyst call entitled
Merck Serono Abandons Oral Cladribine: What Impact Will Its Termination Have on the Multiple Sclerosis Drug Market?
This analyst call was held on July 6, 2011.
Contact us to learn how you can purchase this service and access the recorded event.
Click here to view the invite.
-
June 28, 2011
Based on our Pharmacor
Ovarian Cancer advisory service, Decision Resources is offering an exclusive analyst call entitled
How Will Targeted Therapies Entering the Ovarian Cancer Drug Market Impact Physician Prescribing?
This analyst call was held on June 28, 2011.
Contact us to learn how you can purchase this service and access the recorded event.
Click here to view the invite.
-
June 2, 2011
Based on our Pharmacor
Hepatitis C Virus advisory service, Decision Resources is offering an exclusive analyst call entitled
The Future is Now – How Will the Launches of Victrelis & Incivek Impact the Market and the Regulatory Landscape for Hepatitis C Virus?
This analyst call was held on June 2, 2011.
Contact us to learn how you can purchase this service and access the recorded event.
Click here to view the invite.
Decision Resources Group companies include: